The EPS beat and narrowing loss are positive for a micro-cap biotech, but the $9.5M cash runway (approx. 5-6 quarters at current burn) and reliance on ATM financing introduce dilution risk. Watch for Phase 2 ARDS data in H2 2026 and the ATS presentation on May 20 for near-term catalysts. The non-dilutive collaborations reduce capital burden but are small in absolute size.
INKT drugs
INKT drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 15 $10.72entry
- T+1 · 6mo ago −6.34%α −6.28% · $10.04
- T+5 · 6mo ago +1.40%α +0.44% · $10.87
- T+20 · 5mo ago +16.93%α +14.81% · $12.54
- T+60 · 3mo ago +4.76%α +0.24% · $11.23
Price Chart
How similar events traded
Executive Summary
MiNK Therapeutics reported Q1 2026 EPS of -$0.57, beating consensus of -$0.77 by 26%, with net loss narrowing to $2.7M from $2.8M YoY. The company initiated a randomized Phase 2 trial for agenT-797 in acute lung injury, secured non-dilutive funding for pipeline expansion, and ended the quarter with $9.5M cash after repaying a $5.2M convertible note. The EPS beat is notable for a clinical-stage biotech, but the cash burn and early-stage pipeline keep the impact moderate.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.57 vs consensus -$0.77 (26% beat)
- Net loss $2.7M vs $2.8M YoY; net loss per share improved from -$0.70 to -$0.57
- Cash and equivalents $9.5M as of March 31, 2026, down from $13.4M at year-end 2025
- Repaid $5.2M Agenus convertible note; raised $3.0M via ATM during Q1
- Initiated randomized Phase 2 trial for agenT-797 in severe acute lung injury/ARDS; preliminary data expected H2 2026
- Non-dilutive collaboration with C-Further provides up to $1.1M for PRAME-targeted iNKT therapy in pediatric cancers
- AACR/ASGCT data showed 77% disease control rate in PD-1 refractory gastroesophageal cancer; median PFS 6.9 months with immune induction vs 3.5 months without
- Upcoming ATS presentation on agenT-797 + N-803 for persistent Coccidioides infection on May 20, 2026
Financial Impact
EPS beat of 26% on a -$0.77 consensus; net loss improved $0.1M YoY; cash burn $1.7M in operations during Q1
Risk Factors
- Cash runway limited to ~5-6 quarters at current burn rate; may require additional financing
- Phase 2 ARDS trial is early-stage with binary outcome risk; no approved pharmacologic therapies exist for ARDS
- ATM program dilutes existing shareholders; $3.0M raised in Q1
- Stock is micro-cap ($52M market cap) with low liquidity and high volatility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295757 |
Track record
21 reports on INKT
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +14.37% at T+20 after the May 14, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
- Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
- Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
- Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
- Aug 13, 202613w ago 8-K Mixed 6/10 No price data
- Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
- Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
- May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
- May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers